Randomized, single-blinded, placebo-controlled, parallel-group trial to clarify the acute effect of single nebulized Amphotericin B on cough symptoms in bronchodilator resistive cough patients

Randomized, single-blinded, placebo-controlled, parallel-group trial to clarify the acute effect of single nebulized Amphotericin B on cough symptoms in bronchodilator resistive cough patients - Effect of single nebulized Amphotericin B on cough in bronchodilator resistive cough

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009007

Enrollment

Registered

2012-10-01

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchodilator resistive chronic cough

Interventions

Nebulizer inhalation of 100 mg Amphotericin B Nebulizer inhalation of 0.5 mg Budesonide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with bronchodilator resistive chough lasting eight weeks or more

Exclusion criteria

Exclusion criteria: 1) Patients having abnormal shadow on chest X-ray 2) Patients having wheezing audible 3) Patients having obstructive disorders in pulmonary function testing 4) Patients having severe complications 5) Patients having pulmonary tuberclosis

Design outcomes

Primary

Measure	Time frame
To evaluate cough symptoms using CHQ scores	—

Secondary

Measure	Time frame
To compare the pattern of change in CHQ and FENO after treatment between FACC and non FACC patients	—

Countries

Japan

Contacts

Public ContactKazuo Ueda

Ishikawa-ken Saiseikai Kanazawa Hospital. Pharmacy

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026